Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.

J Neurol Neurosurg Psychiatry 2011 Apr 22;82(4):441-6. Epub 2010 Sep 22.

Department of Neurosurgery, University Hospital Großhadern, Ludwig-Maximilians-Universität München, Munich, Germany.

Background: Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ). Unfortunately, no data are available concerning the predictive value of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation for this important subpopulation. For clarification, a prospective study was conducted.

Methods: Adult patients with a non-resectable glioblastoma were included. A molecular stereotactic biopsy technique was used for tumour characterisation combining histopathological diagnosis with small sample size adjusted methylation-specific PCR (MSP) and sodium bisulfite sequencing. Treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m(2))→TMZ (150-200 mg/m(2) per day for 5 days of every 28-day cycle). The primary end point was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment response (TR). Patients were categorised in the Radiation Therapy Oncology Group (RTOG)-recursive partitioning analysis (RPA) Classes III (N=4), IV (N=12), V (N=28) and VI (N=12).

Results And Discussion: The success rates of MSP and sequence analyses were 100%. The MGMT promoter was methylated in 30/56 tumours, which was associated with an increased PFS (median 56 versus 20 weeks; hazard ratio 0.15; range 0.07 to 0.33; p<0.0001), higher frequency of TR (93.3% vs 46.2%; p=0.0008) and increased OS (median 104 vs 28 weeks; hazard ratio 0.18; range 0.08 to 0.38; p<0.0001). The transient perioperative morbidity was 1.8%.

Conclusion: MGMT promoter methylation has a predominant favourable influence even for the important subpopulation with non-resectable glioblastoma. The molecular stereotactic biopsy technique is safe and effective for predictive evaluation and helps to avoid both over- and undertreatment.

Download full-text PDF

Source
http://jnnp.bmj.com/content/82/4/441.full.pdf
Web Search
http://jnnp.bmj.com/cgi/doi/10.1136/jnnp.2010.214593
Publisher Site
http://dx.doi.org/10.1136/jnnp.2010.214593DOI Listing
April 2011
31 Reads

Publication Analysis

Top Keywords

non-resectable glioblastoma
12
mgmt promoter
8
patients non-resectable
8
rpa classes
4
sample size
4
small sample
4
100% mgmt
4
analyses 100%
4
size adjusted
4
pcr msp
4
msp sequence
4
msp sodium
4
methylation-specific pcr
4
survival treatment
4
sequence analyses
4
adjusted methylation-specific
4
diagnosis small
4
treatment response
4
biopsy technique
4
30/56 tumours
4

Similar Publications